Molecular Pharmacology (USA), Ltd. (MLPH) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED 2026
What happened to Molecular Pharmacology (USA), Ltd. (MLPH) stock?
Molecular Pharmacology (USA), Ltd. (MLPH) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Molecular Pharmacology (USA), Ltd. (MLPH). Molecular Pharmacology (USA) Limited is a development stage company focused on pain and inflammation management products. Their lead product, Tripeptofen, targets everyday pain and is available in various formulations. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for MLPH: MLPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MLPH against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 24 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
MLPH: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Molecular Pharmacology (USA), Ltd. (MLPH) Healthcare & Pipeline Overview
Molecular Pharmacology (USA) Limited, a development stage biotech firm, focuses on developing and commercializing pain and inflammation management products, primarily in Australia and the United States, with its key molecule, Tripeptofen, targeting common everyday pain; the company operates through pharmaceutical distributors and collaborative agreements.
What Is the Investment Thesis for MLPH?
Molecular Pharmacology (USA) Limited presents a high-risk, high-reward investment profile typical of development-stage biotechnology companies. The company's focus on Tripeptofen, a novel analgesic and anti-inflammatory molecule, could address a significant market need for everyday pain management. However, the company's negative P/E ratio of -130.66 reflects its current lack of profitability. Successful clinical trials, regulatory approvals, and commercialization of Tripeptofen are critical value drivers. The agreement with Dermatology Development Corporation for the ThermaLIFE product range could provide an additional revenue stream. Investors should closely monitor the company's progress in clinical development, partnership agreements, and ability to secure funding to support its operations. The company's OTC listing adds another layer of risk due to lower liquidity and disclosure requirements.
Based on FMP financials and quantitative analysis
MLPH Key Highlights
Molecular Pharmacology (USA) Limited is a development stage company focused on pain and inflammation management.
- The company's primary product is Tripeptofen, an analgesic and anti-inflammatory molecule.
- The company markets its products through pharmaceutical distributors and collaborative agreements.
- The company has an agreement with Dermatology Development Corporation to develop and market products based on the ThermaLIFE product range.
- The company's P/E ratio is -130.66, reflecting its current lack of profitability.
Who Are MLPH's Competitors?
MLPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.93 | +1.96% | $325M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
| CRMD CorMedix Inc. | $7.96 | -0.06% | $624M | 885-pillar |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | 875-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are MLPH's Key Strengths?
Proprietary analgesic and anti-inflammatory molecule (Tripeptofen).
- Established relationships with pharmaceutical distributors.
- Agreement with Dermatology Development Corporation for ThermaLIFE products.
- Focus on a specific therapeutic area (pain and inflammation management).
What Are MLPH's Weaknesses?
Development stage company with limited revenue.
- Negative P/E ratio (-130.66).
- Reliance on successful clinical trials and regulatory approvals.
- OTC listing with lower liquidity and disclosure requirements.
What Could Drive MLPH Stock Higher?
Clinical trial results for Tripeptofen.
- Potential regulatory approvals for Tripeptofen in Australia and the United States.
- Development of new formulations and line extensions of Tripeptofen.
- Expansion of the ThermaLIFE product range through the agreement with Dermatology Development Corporation.
What Are the Key Risks for MLPH?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for Tripeptofen.
- Unsuccessful clinical trials.
- Competition from established pharmaceutical companies and other biotech firms.
- Inability to secure funding to support operations.
- Risks associated with OTC trading, including low liquidity and limited disclosure.
What Are the Growth Opportunities for MLPH?
- Expansion of Tripeptofen into new markets: Molecular Pharmacology (USA) Limited has the opportunity to expand the market reach of Tripeptofen beyond Australia and the United States. Entering European and Asian markets, where there is a significant demand for pain management solutions, could drive substantial revenue growth. This expansion would require strategic partnerships with local distributors and navigating regulatory requirements in each new market. The global pain management market is projected to reach $91.5 billion by 2028, presenting a significant opportunity for the company.
- Development of new formulations and line extensions: The company can leverage its existing expertise in pain and inflammation management to develop new formulations and line extensions of Tripeptofen. This could include developing topical creams, extended-release tablets, or combination therapies to address specific patient needs. These new products could command higher prices and expand the company's market share. The market for topical pain relievers is expected to grow at a CAGR of 4.5% from 2021 to 2028.
- Strategic partnerships and collaborations: Molecular Pharmacology (USA) Limited can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships could provide access to funding, expertise, and distribution networks. Collaborating with companies that have established relationships with healthcare providers and payers could significantly enhance the company's market penetration. The pharmaceutical industry is characterized by frequent collaborations and acquisitions, creating opportunities for the company to partner with larger players.
- Expansion of the ThermaLIFE product range: The company's agreement with Dermatology Development Corporation to develop and market products based on the ThermaLIFE product range presents a growth opportunity in the cosmetic and cosmeceutical market. Expanding the product line with new formulations and targeting specific skin conditions could drive revenue growth. The global cosmeceutical market is projected to reach $68.7 billion by 2027, offering a significant opportunity for the company.
- Focus on personalized pain management solutions: Molecular Pharmacology (USA) Limited can differentiate itself by focusing on personalized pain management solutions. This could involve developing diagnostic tools to identify patients who are most likely to respond to Tripeptofen or tailoring treatment regimens based on individual patient characteristics. Personalized medicine is a growing trend in the healthcare industry, and companies that can offer customized solutions are likely to gain a competitive advantage.
What Are MLPH's Competitive Advantages?
- Proprietary analgesic and anti-inflammatory molecule (Tripeptofen).
- Established relationships with pharmaceutical distributors.
- Agreement with Dermatology Development Corporation for ThermaLIFE products.
- Focus on a specific therapeutic area (pain and inflammation management).
What Does MLPH Do?
Molecular Pharmacology (USA) Limited, based in Perth, Australia, is a development stage company dedicated to creating and marketing products for pain and inflammation management. The company operates primarily in Australia and the United States. Through its subsidiary, Molecular Pharmacology Pty. Ltd., the company is developing Tripeptofen, an analgesic and anti-inflammatory molecule intended for the treatment of common everyday pain. Their products are designed to be versatile, offered in various dosage forms, formulations, line extensions, and package configurations to meet diverse patient needs. The company's strategy involves marketing its products through pharmaceutical distributors and establishing collaborative relationships with companies in the United States and Europe. This approach allows them to expand their market reach and leverage the expertise of established players in the pharmaceutical industry. Molecular Pharmacology (USA) Limited also has an agreement with Dermatology Development Corporation to develop and market therapeutic, cosmetic, and cosmeceutical products based on the ThermaLIFE product range and its active ingredient. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited, providing it with a supportive framework as it navigates the challenges of the biotechnology sector.
What Products and Services Does MLPH Offer?
- Develops analgesic and anti-inflammatory molecules.
- Focuses on pain and inflammation management products.
- Commercializes products primarily in Australia and the United States.
- Offers products in various dosage forms and formulations.
- Markets products through pharmaceutical distributors.
- Collaborates with companies in the United States and Europe.
- Develops therapeutic, cosmetic, and cosmeceutical products based on the ThermaLIFE product range.
How Does MLPH Make Money?
- Develops and patents novel analgesic and anti-inflammatory molecules.
- Outlicenses or partners with pharmaceutical companies for commercialization.
- Generates revenue through product sales and licensing agreements.
- Focuses on marketing through pharmaceutical distributors.
What Industry Does MLPH Operate In?
Molecular Pharmacology (USA) Limited operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for pain and inflammation management is substantial, driven by an aging population and increasing prevalence of chronic conditions. The company faces competition from established pharmaceutical companies and other biotech firms developing novel pain therapies. Success in this industry requires strong intellectual property, efficient clinical trial execution, and effective commercialization strategies. The company's collaborative approach and focus on a specific therapeutic area may provide a competitive edge.
Who Are MLPH's Key Customers?
- Pharmaceutical distributors in Australia and the United States.
- Patients seeking pain and inflammation management solutions.
- Dermatology Development Corporation for ThermaLIFE products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 19 days old
- ● Latest filing 164 days ago
- ● No analyst coverage
Financial Health
Molecular Pharmacology (USA), Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Quarterly Financial Performance: Molecular Pharmacology (USA), Ltd.
Revenue for Molecular Pharmacology (USA), Ltd. came in at $0 during Q3 FY2025. The company recorded a net loss of $600, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, MLPH averaged $-0.00 in diluted EPS.
Company Profile
Molecular Pharmacology (USA), Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Jeffrey David Edwards. MLPH has traded publicly since 2009.
MLPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Proprietary analgesic and anti-inflammatory molecule (Tripeptofen).
- Established relationships with pharmaceutical distributors.
- Agreement with Dermatology Development Corporation for ThermaLIFE products.
- Focus on a specific therapeutic area (pain and inflammation management).
Bear Case
- Development stage company with limited revenue.
- Negative P/E ratio (-130.66).
- Reliance on successful clinical trials and regulatory approvals.
- OTC listing with lower liquidity and disclosure requirements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2025 | $0 | -$600 | -$0.0000 |
| Q3 FY2024 | $0 | -$600 | -$0.0000 |
| Q2 FY2024 | $0 | -$600 | -$0.0000 |
| Q1 FY2024 | $0 | -$4,920 | -$0.0002 |
Q3 FY2025 · filed 31 Mar 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
MLPH Latest News
No recent news available for MLPH.
Leadership: Jeffrey David Edwards
CEO
Further research would be needed to provide details on his career history, education, and previous roles.
Track Record: Information on Jeffrey David Edwards' track record is not available in the provided data. Further research would be needed to provide details on his key achievements, strategic decisions, and company milestones under his leadership.
MLPH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that the company may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in these companies.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of business failure.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with the company's operations.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Subsidiary of PharmaNet Group Limited.
- Focus on developing pharmaceutical products.
- Agreement with Dermatology Development Corporation.
- Presence in the biotechnology sector.
Molecular Pharmacology (USA), Ltd. Healthcare Stock: Key Questions Answered
What happened to Molecular Pharmacology (USA), Ltd. (MLPH) stock?
Molecular Pharmacology (USA), Ltd. (MLPH) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
Can I still buy MLPH shares?
No. MLPH stopped trading on public markets in April 2026, so the shares are not available through a broker. Anything you see quoted for MLPH elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MLPH stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Molecular Pharmacology (USA), Ltd.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Molecular Pharmacology (USA), Ltd. do?
Molecular Pharmacology (USA) Limited is a development-stage biotechnology company focused on creating and commercializing pain and inflammation management products. Their primary focus is on Tripeptofen, an analgesic and anti-inflammatory molecule intended for everyday pain relief.
What do analysts say about MLPH stock?
As of 2026-03-17, there is no available analyst coverage for Molecular Pharmacology (USA), Ltd. due to its OTC listing and development stage. The company's valuation is difficult to assess given its negative P/E ratio and lack of revenue.
What are the main risks for MLPH?
The main risks for Molecular Pharmacology (USA), Ltd. include the typical challenges associated with development-stage biotechnology companies. These include the risk of failure in clinical trials, the inability to obtain regulatory approvals, and the need to secure additional funding to support operations.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company due to its OTC listing and development stage.